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gologic diseases marketed in Japan. Contact dermatitis (CD) is one of well-known 
adverse events provoked by fradiomycin sulfate. The objectives of this study were to 
investigate the incidence of CD after the prescription of topical drugs containing fra-
diomycin in clinical practice and to assess background characteristics of the patients 
who were diagnosed CD by using Japanese health care database (HDB). Methods: 
The data were extracted from Japanese HDB (MinaCare Co. Ltd) which contained 
data from people covered by employment-based insurances as of April 2013. We 
classified the patients into three groups with prescription of F/M, fradiomycin sul-
fate - betamethasone sodium phosphate combination ointment (F/B, comparable 
to F/M) or betamethasone sodium phosphate solution (B, as a negative control), 
respectively. The ICD-10 classification was used to identify CD required medication 
after the prescription. Background characteristics of the patients who were diag-
nosed CD after the prescription was also investigated. Results: Out of 1,223,905 
patients (male: 531,030, female: 692,875), we have identified the F/M group (20,702 
patients), the F/B group (5,540 patients) and the B group (108,810 patients). In the F/M 
group, CD which was suspected causal relationship with the drug was detected in 
around 0.25% of patients according to the chronological order of the prescription and 
diagnosis in claim database. Similar tendency was observed in the F/B group, while 
lower incidence of CD was observed in the B group. ConClusions: We utilized 
MinaCare HDB to assess the incidence of CD required medication after topical drugs 
prescription in real clinical settings. CD was detected at higher incidence with the 
drugs containing fradiomycin than steroid alone. While further analysis is needed 
for more accuracy, our approach designed to diminish limitations’ influences was 
useful to assess risk and benefit of drugs.
SenSory SyStemS DiSorDerS – Cost Studies
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objeCtives: sVMA is a serious, sight-threatening and progressive condition which, 
if untreated, leads to irreversible retinal damage, vision loss, and reduced visual 
function. Current standard of care for sVMA is vitrectomy, which has a high rate 
of complications and requires patients to maintain a “head-down” position for up 
to two weeks, resulting in additional surgical costs, discomfort and significant car-
egiver burden. Ocriplasmin (Jetrea®), a single intravitreal injection to resolve sVMA, 
was recently approved in the UK and US. A budget impact analysis was performed 
to test the hypothesis that ocriplasmin can provide cost savings to a hypothetical 
managed care plan by reducing total vitrectomies to resolve sVMA. Methods: 
An Excel-based economic model was designed from the perspective of a managed 
care plan to quantify total direct costs of treating patients with sVMA across two 
scenarios: 1) the current treatment paradigm, consisting of clinical management 
or vitrectomy, and 2) future treatment paradigm, which also includes ocriplasmin 
or ocriplasmin followed by vitrectomy. The model assumes costs are all-inclusive 
over a 1-year period and accounts for diagnosis and monitoring, vitrectomy, intra-
vitreal injection procedures, pharmacy, and treatment of complications. Costs were 
obtained from 2012 Medicare fee-for-service rates and Medicare claims using the 
2005-2009 Outpatient and Part B 5% Standard Analytical Files. Results: Based on 
an aggregate market penetration of 23% (replacing 44% of vitrectomy patients and 
2.5% of clinical management patients), ocriplasmin reduces total vitrectomies by 
35%, resulting in cost savings of $27,884 per year to a 1 million-member health plan. 
Major cost impact drivers include cost of vitrectomy and associated complications, 
cost of ocriplasmin and complications, and percent of ocriplasmin patients requir-
ing vitrectomy. ConClusions: In addition to reducing surgical complications and 
improving patient quality of life, ocriplasmin has the potential to reduce direct 
medical costs to a managed care plan for treating sVMA.
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objeCtives: Identify the real world treatment patterns, medical history, resource 
use and costs of patients with choroidal neovascularization (CNV) secondary to 
pathologic myopia (PM), or myopic CNV (mCNV), in Canada. Methods: Ninety-
eight (98) patients with mCNV from 16 centres across Canada were included in this 
retrospective study. Medical records covering at least one year and up to two years 
of follow up data from the CNV diagnosis were analyzed to gather all information 
related to mCNV. Results: Patients had a mean age of 55.0 years (range: 22 - 82 
years) at the time of their first lifetime CNV episode. Baseline characteristics of 
patients showed that 71.4% of participants were female, 57.1% and 28.6% had sub-
foveal or juxtafoveal CNV in the affected eye, respectively. The bilaterality of mCNV 
was 13.3%. The approximate mean Snellen score at the time of CNV diagnosis was 
20/125 in the affected eye and 20/80 in the fellow eye. Forty-nine percent (49%) of 
patients had visual acuity (VA) severity in the affected eye of normal/mild vision 
loss (VA 20/20 to > 20/80), 19% moderate vision loss (VA 20/80 to > 20/200), and 32% 
severe vision loss/nearly blind (VA ≤ 20/200). The mean duration of CNV episode was 
0.78 years. Almost 90% of mCNV patients consulted a Retina Specialist (on average 
6.0 times/year), 11.2% of patients had to visit the ER and 2.0% were admitted to 
hospital due to mCNV. Most patients were treated with an anti-VEGF therapy and 
received on average 3.8 injections per year. The annual average myopic CNV-related 
cost per patient was $3,433. The cost was $2,964, $3,595 and $4,060 for patients with 
mild, moderate and severe vision loss, respectively. ConClusions: This is the first 
this study, 211 patients with mCNV were matched for demographic characteristics 
with 211 PM controls. Results: The prevalence of CNV secondary to PM was esti-
mated to be 0.084% in the general adult population with an annual incidence of 
0.0061%. Amongst PM patients, 6.2% develop CNV. The bilaterality of mCNV was 10%. 
CNV was mostly subfoveal (87%) and was more common in women than men. At the 
time of CNV diagnosis, the mean Snellen score was 20/100 in the affected eye. The 
most common treatments were verteporfin and laser photocoagulation. The burden 
of resource use, including hospitalizations and emergency, general practitioners 
clinic and ophthalmology visits, is more important in mCNV patients than in PM 
patients (p< 0.01). ConClusions: In a Canadian real-world setting, the prevalence 
and the annual incidence of myopic CNV was 0.084% and 0.0061%, respectively. This 
is the first Canadian study investigating the epidemiology of myopic CNV and the 
results will help us better understand this debilitating disease.
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objeCtives: Few data on the epidemiology and costs of vitreomacular traction 
(VMT) in France are available. Therefore, a study was conducted to evaluate the 
management and associated costs of the most severe forms of this condition, 
which are treated by vitrectomy. Methods: A retrospective, observational study 
was conducted using the French hospital discharge database (PMSI) by identify-
ing all patients having undergone a vitrectomy in 2009 for VMT, with or without 
a macular hole. There was a follow-up period of 2 years. Medical records were 
analyzed by health informatics doctors from 4 hospitals in order to establish an 
extraction algorithm for the relevant patient stays, in the absence of formal VMT 
codes. Patient characteristics, length of stay, rehospitalization for an ophthalmic 
reason, and hospital charges were described. Results: In 2009, 3,463 patients 
were hospitalized for a first-time vitrectomy related to VMT. The mean age was 
68.9 years, with 59% being women. The initial length of stay was primarily 2 to 3 
days (respectively for 21% and 55% of patients, mean of 2.8). Approximately 11% 
of patients underwent concomitant cataract surgery. During the 2-year follow-up, 
48.6% of patients were rehospitalized for an ophthalmic reason, mainly for cata-
ract surgery (75.7%) or retinal tear and/or detachment (14.8%), with an average stay 
of 3 days. The mean charge for the initial stay was € 2,697 and the mean charge for 
rehospitalization for ophthalmic reasons was € 2,930 per stay. ConClusions: This 
study is the first providing extensive data on epidemiology and hospital journeys 
for patients suffering from VMT and treated by vitrectomy in France. Our study 
shows that there is a high rate of rehospitalization for ophthalmic causes at 2 
years post-vitrectomy, and the economic impact is sizeable. Early treatment of 
VMT could reduce the need for surgery and the complications of advanced forms 
of this condition.
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objeCtives: Describe the epidemiological characteristics and treatments for 
chronic plaque psoriasis in a large, Canadian, real-world dataset. Methods: This 
was an observational, retrospective cohort of patients ≥ 18 years who, between 
2008 and 2012 received a diagnosis of psoriasis (overall, scalp, nail, chronic 
plaque, pustular, palmoplantar pustulosis and guttate psoriasis) identified 
by ICD9-10 and/or text coding, and who were prescribed at least 1 treatment. 
Data were retrieved from the Southwestern Ontario (SWO) database, which is 
a representative primary care, researchable database of over 325,000 unique 
patient records in Ontario, Canada. Results: Among 325,618 patients in the 
SWO database, 7,935 patients had a diagnosis of psoriasis between January 1, 
2008 and December 31, 2012 (prevalence 2.44%). Of these, 98% (n=7,776) were 
treated. Chronic plaque psoriasis was the most common subtype of psoriasis 
(85%, n=6,610), followed by scalp psoriasis (50%, n=3,888) in patients receiving 
treatment. Among chronic plaque psoriasis patients, duration of disease ranged 
from 1 to 23 years. Mean age at diagnosis was 31 (sd=12) years. Patients with mild 
disease were generally treated with topicals, most commonly corticosteroids 
(65%), salicylic acid (28%) and/or coal tar (19%). Phototherapy (NB-UVB, 
psoralen+UVA) and oral systemic agents (acitretin, cyclosporine, methotrexate) 
were also prescribed. Twenty eight percent (28%) of chronic plaque psoriasis 
patients had a moderate to severe condition. About 60% of moderate to severe 
patients were treated with phototherapy, whereas 33% were prescribed biologics 
(adalimumab, etanercept, infliximab, ustekinumab). ConClusions: Psoriasis 
is a significant problem in primary care, affecting over 2% of the population. 
Of these, 85% have chronic plaque psoriasis and 28% are considered moderate 
to severe. Results of this study confirm those observed in the literature. This 
real-world database may be used as a resource for further examination of the 
effectiveness of psoriasis treatment and health resource use.
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objeCtives: Fradiomycin sulfate - methylprednisolone combination ointment (F/M) 
is an anti-inflammatory topical drug indicated for ophthalmologic or otorhinolaryn-
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vs. 62.2%, p= 0.24), but reported higher mean levels of absenteeism (12.64% vs. 5.00%, 
p= 0.0014), presenteeism (32.71% vs. 15.49%, p< 0.0001), overall work impairment 
(37.32% vs. 18.26%, p< 0.0001) and activity impairment (45.93 vs. 26.90, p< 0.0001) 
relative to controls. Mean health care utilization in the prior 6 months was greater 
among cases than controls for visits to traditional health care providers (8.39 vs. 
5.03, p< 0.0001), general practitioners (1.72 vs. 1.25, p= 0.0043), allergists (0.49 vs. 0.07, 
p< 0.0001), dermatologists (0.40 vs. 0.16, p= 0.0004), emergency rooms (0.50 vs. 0.33, 
p= 0.0608), and hospitalizations (0.36 vs. 0.23, p= 0.0985). ConClusions: Using CH 
as a proxy for CIU, a considerable economic burden on patients was evident in work 
productivity and use of health care compared to patients without CH with similar 
sociodemographic characteristics.
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objeCtives: To compare the number of 1st-line and 2nd-line intravitreal anti-
VEGF injections and associated costs in patients with neovascular age-related 
macular degeneration (AMD) treated with aflibercept (AFB) or ranibizumab 
(RBZ). Methods: A retrospective cohort study of US claims data of patients 
who: initiated 1st- or 2nd-line ITV anti-VEGF treatment with RBZ or AFB between 
1/18/2011 and 7/31/2013 (index date), had no evidence of bilateral disease, were 
aged ≥ 18 years on index date, had ≥ 12 months of continuous insurance enrollment 
before index date (baseline period), were diagnosed with AMD (ICD-9-CM 362.52) 
during baseline period or on index date, and had ≥ 12 months of follow-up enroll-
ment post index date without switching anti-VEGF agents. Outcomes (number of 
anti-VEGF injections and their associated costs) were assessed within 12-month 
follow-up period. Multivariable regressions compared outcomes between AFB and 
RBZ, adjusting for confounding patient characteristics. Results: A total of 115 
1st-line AFB, 431 2nd-line AFB, 481 1st-line RBZ, and 174 2nd-line RBZ patients met 
the inclusion criteria. Mean [SD] number of injections was similar for AFB and RBZ 
patients for 1st- (5.0 [2.7] and 5.0 [3.1], respectively) and 2nd-line (5.7 [2.5] and 5.8 
[3.1], respectively). Mean anti-VEGF therapy-related costs [SD] were comparable for 
AFB and RBZ patients for 1st- ($9,155 [$11,420] and $9,241 [$10,547], respectively) 
and 2nd-line ($10,485 [$11,734] and $10,935 [$13,411], respectively). Multivariable 
regression determined that, for both 1st- and 2nd-line patients, neither number 
nor costs of injections differed significantly between AFB and RBZ (treating RBZ 
as reference: Incidence Rate Ratio [IRR]= 0.99, 95% confidence interval [CI]= 0.87-
1.13, P= 0.871 [1st-line]; IRR= 0.97, 95%CI= 0.88-1.06, P= 0.476 [2nd-line]; Cost Ratio 
[CR]= 0.96, 95%CI= 0.82-1.11, P= 0.582 [1st-line]; CR= 0.89, 95%CI= 0.79-1.01, P= 0.064 
[2nd-line]). ConClusions: Injection frequency and costs over 12 months were 
similar for AFB and RBZ in this analysis of AMD patients initiating 1st- or 2nd-line 
anti-VEGF treatment in a real-world setting.
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objeCtives: The objective of this study was to describe health care costs associ-
ated with the management of psoriasis in patients newly initiated on a biologic 
or methotrexate (MTX). Methods: Continuously enrolled adult patients with ≥ 2 
inpatient or outpatient psoriasis diagnoses were selected from the MarketScan 
Commercial Claims database (2005-2009). The first biologic or MTX prescription 
date was defined as the index date. “MTX initiators” had not used biologics, non-
biologic conventional systemic therapies, or phototherapy 6 months before the 
index date. “Biologic initiators” were required to be biologic-naïve only before the 
index date. Health care costs were estimated from a US payer perspective (2011 
US dollars) over the 12-month period following the index date, based on payments 
for all medical services and psoriasis related diagnosis as a subset. Physician 
office visits, monitoring, inpatient hospitalizations, and emergency department 
visits were also captured. Results: A total of 2,642 MTX initiators and 6,702 bio-
logic initiators met the eligibility criteria. MTX initiators had a mean annual total 
health care cost of $12,548, of which 30.7% was psoriasis-related. Pharmacy costs 
accounted for $3,182 of the psoriasis-related costs, office care and monitoring 
costs accounted for $501, and urgent care costs accounted for $166. Biologic initia-
tors had an average annual total health care cost of $28,752, of which 72.0% was 
psoriasis-related. Pharmacy costs accounted for $19,997 of the psoriasis-related 
total costs, office care and monitoring cost for $538, and urgent care costs for 
$166. ConClusions: Psoriasis patients initiating on MTX or a biologic incurred 
substantial health care costs. Pharmacy costs account for the majority of the 
psoriasis-related costs.
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study worldwide investigating the burden of disease. Myopic CNV-related costs of 
care are substantial and increasing with the severity of vision loss.
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objeCtives: Estimate health care utilization and costs of co-morbidities in patients 
with psoriasis. Methods: A retrospective cohort analysis was conducted using 
the Truven MarketScan data®. Inclusion criteria were adult patients with at least 
2 diagnosis of psoriasis (ICD-9-CM: 696.1) on different dates between January 1st, 
2010 and December 31st, 2011, with at least one psoriasis diagnosis in year 2010 
and with continuous enrollment of medical and pharmacy benefits in year 2010 
and 2011. Patients were divided into two groups with and without comorbidity of 
interest in year 2010. Multiple regressions were conducted to compare all cause 
health care utilization (Poisson regression) and costs (gamma regression or two 
part models; 95% confidence intervals (CI) were calculated using bootstrapping 
method) in year 2011 between patients with and without comorbidity of interest, 
controlling for age, gender, and region and psoriasis severity in year 2010. Results: 
A total of 56,406 patients (mean age 51.71 years) were included in the analyses. 
The top five prevalent co-morbidities were hypertension (34.49%), hyperlipidemia 
(33.79%), cardiovascular disease (17.44%), diabetes (14.36%) and psoriatic arthritis 
(9.94 %). The all cause incidence rate ratio (95% CI) of emergency room visits, hos-
pitalization, outpatient visits for patients with at least one co-morbidity was 1.84 
(1.75-1.94); 2.03 (1.87-2.19); 1.49 (1.47-1.51) respectively compared to patients with 
no co-morbidities (all, p< 0.0001). The adjusted all cause health care costs difference 
was $6640 ($6255-$7024) for patients with co-morbidities as compared patients 
with no co-morbidities. The mean (95% CI) all cause adjusted cost difference for 
psoriatic patients with co-morbidities as compared to psoriatic patients without co-
morbidities was $4,522 ($4034-$5011), $1,635 ($1,188-$2,082), $8,275.1 ($7,461-$9,089), 
$6,911 ($6,271-$7,552) and $9,914 ($9,216-$10,613) for hypertension, hyperlipidemia, 
cardiovascular disease, diabetes and psoriatic arthritis respectively. ConClusions: 
Comorbidities continue to have a significant economic burden in patients with 
psoriasis in the United States.
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objeCtives: Estimate direct and indirect costs of depression and anxiety in 
patients with psoriasis (PsO). Methods: Retrospective cohort analysis was con-
ducted using Truven MarketScan data®. Adult patients with at least 2 diagnosis of 
PsO (ICD-9-CM: 696.1) between year 2010 and 2011 (at least one PsO diagnosis in 
year 2010) having continuous enrollment of medical and pharmacy benefits were 
included. Patients with Health and Productivity Management data for 2011 were 
included for the indirect cost analysis, including costs associated with absence 
of leave (ABS), short term disability (STD), and long term disability (LTD). Indirect 
costs were calculated using average 2011 hourly wage data for all US private indus-
tries (number of ABS/STD/LTD days * 8 hours * an average hourly wage). Multiple 
regressions were conducted to compare year 2011 direct costs and indirect costs 
(gamma regression or two part models) between patients with and without depres-
sion or anxiety respectively, controlling for age, gender, and region and PsO sever-
ity in year 2010. Results: Among a total of 56,406 PsO patients (mean age 52 
years), 7.9% patients with depression and 5.7% with anxiety in year 2010 were 
included in the direct cost analyses. A total of 1,434 patients for ABS, 5,878 for 
STD and 5,692 for LTD were included in the indirect cost analyses. The adjusted 
health care costs were significantly higher for patients with depression ($20,794 
vs. $14,028) or anxiety ($18,501 vs. $14,320) than those without (p< 0.001 for all). 
The major differences between indirect costs were STD costs whereby the adjusted 
mean difference between patients with depression vs. without depression were 
$997 (95% confidence interval (CI) $432-1561), between patients with anxiety vs. 
without was $268 (95% CI $-158-790). ConClusions: Significant proportion of PsO 
patients had depression and anxiety, and patients with depression and anxiety 
have substantial higher direct and indirect costs than those without.
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objeCtives: To assess the economic burden of patients with chronic idiopathic 
urticaria (CIU) in terms of labor force participation, work and activity impairment, 
and health care utilization, using patients currently treated for chronic hives 
(CH) as a proxy. Methods: Data were obtained from the US National Health and 
Wellness Survey (NHWS) in 2010-2012, representative of US adult population in 
terms of age, sex, and ethnicity. Measures included labor force participation, the 
Work Productivity and Activity Impairment questionnaire, and self-reported health 
care use in the prior 6 months. Respondents indicating current use of a prescrip-
tion for CH (cases) were matched 1:4 to those who never experienced CH (controls), 
using survey year, sex, race, age (±2 years), and Charlson comorbidity index (CCI) 
category (0, 1-2, 3-4, or 5+), and compared using t-test and chi-square. Results: 
Cases (n= 253) and controls (n= 1,012) did not significantly differ in terms of age, 
body mass index, marital status, educational attainment, or mean CCI (all p> 0.05). 
Currently-treated CH patients participated in the labor force at a similar rate (58.1% 
